@prolynxinc.com.bsky.social
Prolynx develops ultra-long-acting medicines for obesity and metabolic diseases, advancing extended-duration therapeutics for monthly and quarterly dosing to support more consistent long-term treatment.
ICYMI: We welcomed Chris Boulton as CEO and announced a $70M Series A to advance ultra-long-acting therapies for obesity and metabolic disease.
We’re encouraged by the engagement around our extended-duration approaches and look forward to sharing continued progress. #medsky https://bit.ly/4a6LdhP
Biotech News Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer Prolynx logo top right
Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/4a6LdhP #biosky
11.12.2025 12:04 — 👍 3 🔁 0 💬 0 📌 0